As such, early phase clinical trials (NCT02763384 and NCT01319864) are trialling the use of CXCR4 inhibitors such as plerixafor and BL-8040 in relapsed ALL. This evidence concerns the gene CXCR4 and acute lymphoblastic leukemia.